SEC Form 4 · accession 0001615219-17-000010
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Wessel
Officer — Chief Medical Officer
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 9:03 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.58 | Jan 18, 2017 | A | 85,000 | A | — | Jan 18, 2027 | Common Stock | 85,000 | 85,000 | D |
Explanation of responses
- F1The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017.